Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 2, 1998, Pages 565-573

  Wilczynski, Stephen W ^a   Erasmus, Jeremy J ^a   Petros, William P ^a   Vredenburgh, James J ^a   Folz, Rodney J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; COUGHING; DRUG MEGADOSE; DYSPNEA; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; PRIORITY JOURNAL; VITAL CAPACITY;

EID: 0031913482     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.2.9705072     Document Type: Article

References (35)

1. Cherniack, R. M., J. Abrams, and A. R. Kalica. 1994. Pulmonary disease associated with breast cancer therapy. Am. J. Respir. Crit. Care Med. 150:1169-1173.
2. Demirer, T., C. H. Weaver, C. D. Buckner, F. B. Peterson, W. I. Bensinger, J. Sanders, R. A. Clift, K. Lilleby, C. Anasette, P. Martin, R. Storg, T. Chauncey, K. Doney, K. Sullivan, and F. R. Appelbaum. 1995. High-dose cyclophosphamide, carmustine and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin. Oncol. 13:596-602.
3. Weaver, C. H., F. R. Appelbaum, F. B. Peterson, R. Clift, J. Singer, O. Press, W. Bensinger, J. Bianco, P. Martin, C. Anasetti, C. Badger, J. Deeg, K. Dony, J. A. Hansen, E. Petersdorf, S. Rowley, R. Storb, K. Sullivan, R. Witherspoon, P. Weiden, and C. D. Buckner. 1993. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J. Clin. Oncol. 11:1329-1335.
4. Reece, D., M. Barnett, J. Shepard, D. Hogge, R. Klasa, S. Nantel, H. Sutherland, H. Klingemann, R. Fairey, N. Voss, J. Connors, S. O'Reilly, J. Spinelli, and G. Phillips. 1995. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/-P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451-456.
5. Peters, W. P., M. Ross, and J. J. Vredenburgh. 1993. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol. 11:1132-1143.
6. Todd, N. W., W. P. Peters, A. H. Ost, V. L. Roggli, and C. A. Piantadosi. 1993. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am. Rev. Respir. Dis. 147:1264-1270.
7. Jones, R. B., S. Matthes, E. J. Shpall, J. H. Fisher, S. M. Stemmer, C. Dufton, J. K. Stephens, and S. I. Bearman. 1993. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J. Natl. Cancer Inst. 85:640-647.
8. Weiner, R. S., M. M. Boymer, R. P. Gale, E. Gluckman, H. E. M. Kay, H.-J. Kolb, A. J. Hartz, and A. A. Rimm. 1986. Interstitial pneumonitis after hone marrow transplantation. Ann. Intern. Med. 104:168-175.
9. Wingard, J. R., E. D. Mellits, M. B. Sostrin, D. Y.-H. Chen, W. H. Burns, O. W. Santos, H. M. Vriesendorp, W. E. Beschorner, and R. Saral. 1988. Interstitial pneumonitis after allogeneic hone marrow transplantation. Medicine 67:175-186.
10. Robbins, R. A., J. Linder, M. G. Stahl, A. B. Thompson, III, W. Haire, A. Kessinger, J. O. Armitage, M. Arneson, G. Woods, W. P. Vaughan, and S. I. Rennard. 1989. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am. J. Med. 87:511-518.
11. Agusti, C., J. Ramirez, C. Picado, A. Xaubet, E. Carreras, E. Ballester, A. Torres, C. Battochia, and R. Rodriguez-Roisin. 1995. Diffuse alveolar hemorrhage in allogeneic bone marrow transplantation. Am. J. Respir. Crit. Care Med. 151:1006-1010.
12. Srivastava, A., D. Gottlieb, and K. F. Bradstock. 1995. Diffuse alveolar hemorrhage associated with microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant. 15:863-867.
13. Budman, D. R., W. Wood, I. C. Henderson, A. H. Korzun, R. Cooper, J. Younger, R. D. Hart, A. Moore, J. Ellerton, L. Norton, C. Ferree, A. Colangelo, and O. R. McIntyre. 1992. Initial findings of CALGB 8541: a dose and dose intensity trial of cyclophosphamide (C), doxorubicin (A), and 5-fluorouracil (F) as adjuvant treatment of stage II, node +, female breast cancer. Proc. Am. Soc. Clin. Oncol. 11:51.
14. Peters, W. P., E. J. Shpall, R. B. Jones, G. A. Olsen, R. C. Bast, Jr., J. P. Gockerman, and J. O. Moore. 1988. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J. Clin. Oncol. 6:1368-1376.
15. Peters, W. P., R. Davis, E. J. Shpall, R. B. Jones, M. Ross, L. Marks, L. Norton, and D. Hurd. 1990. Adjuvant chemotherapy involving high dose combination of cyclophosphamide, cisplatin and carmustine (CPA/CDDP/BCNU) and autologous bone marrow support (ABMS) for stage II/III breast cancer involving ten or more lymph nodes (CALGB 8782): a preliminary report. Proc. Am. Soc. Clin. Oncol. 9:22.
16. Tannock, I., N. Boyd, G. DeBore, C. Erlihman, S. Fine, G. Larocque, C. Mayers, D. Perrault, and H. Sutherland. 1988. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol. 6:1377-1387.
17. Jones, R. B., S. Matthes, D. Kemme, C. Dufton, and S. Kernan. 1994. Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions. Cancer Chemother. Pharmacol. 35:59-63.
18. American Thoracic Society. 1995. Standardization of spirometry. Am. J. Respir. Crit. Care Med. 152:1107-1136.
19. American Thoracic Society. 1995. Single-breath carbon monoxide diffusing capacity (transfer factor). Am. J. Respir. Crit. Care Med. 152: 2185-2198.
20. American Thoracic Society. 1991. Lung function testing: selection of reference values and interpretative strategies. Am. Rev. Respir. Dis. 144: 1202-1218.
21. Owens, C. M., T. W. Evans, B. F. Keogh, and D. M. Hansell. 1994. Computed tomography in established adult respiratory distress syndrome: correlation with lung injury score. Chest 106:1815-1821.
22. Kuhns, L., and J. Seeger. 1983. Tomography Variants. Year Book Medical Publishers, Inc., Chicago.
23. Vogler, J., III, C. Helms, and P. Callen. 1986. Normal Variants and Pitfalls in Imaging, W. B. Saunders Company, Philadelphia.
24. Cooper, J. A. D., Jr., D. A. White, and R. A. Matthay. 1986. Drug-induced pulmonary disease, part 1: cylotoxic drugs. Am. Rev. Respir. Dis. 133:321-340.
25. Twohig, K. J., and R. A. Mathay. 1990. Pulmonary effects of cytotoxic agents other than bleomycin. Clin. Chest Med. 11:31-54.
26. Smith, A. C. 1989. The pulmonary toxicity of nitrosoureas. Pharmacol. Ther. 41:443-460.
27. Weiss, R. B., D. S. Poster, and J. S. Penta. 1981. The nitrosoureas and pulmonary toxicity. Cancer Treat. Rev. 8:111-125.
28. Mitsudo, S. M., E. S. Greenwald, B. Banerji, and L. Koss. 1984. BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung drug induced pulmonary changes. Cancer 54:751-755.
29. Aronin, P. A., M. S. Mahaley, Jr., S. A. Rudnick, L. Dudka, J. F. Donohue, R. G. Selker, and P. Moore. 1980. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. N. Engl. J. Med. 303: 183-188.
30. Durant, J. R., M. J. Norgard, T. M. Murad, A. A. Bartolucci, and K. H. Langford. 1979. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann. Intern. Med. 90:191-194.
31. Phillips, G. L., J. W. Fay, G. P. Herzig, R. H. Herzig, R. S. Weiner, S. N. Wolff, H. M. Lazarus, C. Karanes, W. E. Ross, and B. S. Kramer. 1983. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #436650 and cryopreserved autologous marrow transplantation for refractory cancer: a phase I-II study. Cancer 52:1792-1802.
32. Selker, R. G., S. A. Jacobs, P. B. Moore, M. Wald, E. R. Fisher, M. Cohen, and P. Bellot. 1980. 1,3-Bis(2-chloroethyl)-1-nitrosurea (BCNU)-induced pulmonary fibrosis. Neurosurgery 7:560-565.
33. Jones, R. B., S. Matthes, C. Dufton, S. I. Bearman, S. M. Stemmer, S. Meyers, and E. J. Shpall. 1993. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. Breast Cancer Res. Treat. 26:S11-S17.
34. Bergin, C. J., D. Y. Bell, C. L. Coblentz, C. Chiles, G. Gamsu, N. R. MacIntyre, R. E. Coleman, and C. E. Putnam. 1989. Sarcoidosis: correlation of pulmonary parenchymal pattern at CT with results of pulmonary function tests. Radiology 171:619-624.
35. Muller, N. L., J. B. Mawson, J. R. Mathieson, R. Abboud, D. N. Ostrow, and P. Champion. 1989. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology 171:613-618.